[转移性去势抵抗性前列腺癌：基于当前数据考量的卡巴他赛应用]
[Metastatic castration-resistant prostate cancer : Use of cabazitaxel taking into consideration current data].
作者信息
Gschwend J E, Albers P, Bögemann M, Goebell P, Heidenreich A, Klier J, König F, Machtens S, Pantel K, Thomas C
机构信息
Klinik und Poliklinik für Urologie, Universitätsklinikum rechts der Isar der Technischen Universität München, Ismaninger Straße 22, 81675, München, Deutschland.
Urologische Klinik und Poliklinik, Universität Düsseldorf, Düsseldorf, Deutschland.
出版信息
Urologe A. 2018 Jan;57(1):34-39. doi: 10.1007/s00120-017-0533-y.
BACKGROUND
At the 2016 ASCO annual meeting, new data from two randomized phase III studies concerning taxane-based chemotherapy as a treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) were presented.
OBJECTIVES
The focus is on the clinical impact of these data.
MATERIALS AND METHODS
A group of German experts in the field of urogenital-oncologic expertise discussed the clinical impact with respect to the current data.
RESULTS
The study results support the current clinical data. They confirm the efficacy and safety of cabazitaxel beyond first-line therapy with docetaxel for patients with mCRPC.
CONCLUSIONS
Cabazitaxel is an important treatment option after docetaxel progression. With respect to the performance status of a patient, it is adequate to reduce the dosage to 20 mg/m cabazitaxel.
背景
在2016年美国临床肿瘤学会（ASCO）年会上，公布了两项随机III期研究的新数据，这些研究涉及以紫杉烷为基础的化疗作为转移性去势抵抗性前列腺癌（mCRPC）患者的一种治疗选择。
目的
重点在于这些数据的临床影响。
材料与方法
一组德国泌尿生殖肿瘤学领域的专家就当前数据的临床影响进行了讨论。
结果
研究结果支持当前临床数据。它们证实了卡巴他赛在多西他赛一线治疗失败后用于mCRPC患者的疗效和安全性。
结论
卡巴他赛是多西他赛治疗进展后的一种重要治疗选择。就患者的体能状态而言，将卡巴他赛剂量降至20mg/m²是合适的。
Zotero 插件